Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Defensin (HNP-1)
Also known as: HNP-1, HNP1, Human Neutrophil Defensin 1
Over 1,000 PubMed papers cover defensin biology, yet zero human clinical trials have been completed. Human Neutrophil Peptide-1 (HNP-1) is a 30-amino-acid alpha-defensin that makes up 5 to 7 percent of total neutrophil protein. It kills bacteria, fungi, and enveloped viruses by punching holes in their membranes. The catch: no one has formally tested exogenous HNP-1 in humans as a therapeutic agent. Manufacturing is the bottleneck. Three intramolecular disulfide bonds must form in a precise pattern, making production expensive and quality verification difficult. Immunology researchers studying innate defense mechanisms use it most; as a lab reagent, it runs roughly $250 per 0.1 mg.
What Is Defensin (HNP-1)?
Human Neutrophil Peptide-1 (HNP-1) is an alpha-defensin stored in neutrophil azurophilic granules and one of the first-line antimicrobial peptides your immune system deploys. Over a thousand published papers exist, but not a single human clinical trial. When neutrophils detect infection, they release HNP-1 in bulk. The peptide carries a net +3 charge at physiological pH. That cationic charge pulls it toward the negatively charged membranes of bacteria, fungi, and enveloped viruses. Once bound, HNP-1 oligomerizes, inserts into the lipid bilayer, and forms pores that collapse transmembrane gradients. The result is osmotic lysis.
The peptide also does something more interesting. It recruits immune cells. HNP-1 binds CCR6 on immature dendritic cells and memory T cells, functioning as a chemokine. It promotes dendritic cell maturation, upregulates MHC class II expression, and activates macrophages through TLR4-dependent NF-kB signaling. This means HNP-1 connects innate and adaptive immunity; it kills pathogens directly and then calls in reinforcements.
Anti-HIV activity has been confirmed in cell-free assays (Chang et al., 2005)[1]. But a 2015 study in epithelial cell models [2] found HNP-1 disrupts epithelial tight junctions, increasing HIV traversal of mucosal barriers. That paradox alone makes clinical development complicated.
Research-grade HNP-1 costs $250 to $400 per 0.1 mg and is sold only as a lab reagent. No compounded versions exist. The gray market has essentially zero availability. Anyone exploring this compound is working in a serious research context.
How Defensin (HNP-1) Works
HNP-1 works through two distinct pathways: direct membrane destruction and receptor-mediated immune signaling.
The antimicrobial mechanism is straightforward. HNP-1 carries a net +3 cationic charge. Microbial membranes are rich in anionic phospholipids; mammalian membranes are mostly zwitterionic. That charge difference creates selectivity. HNP-1 binds the microbial surface, oligomerizes, and inserts into the bilayer to form multimeric pores. Transmembrane gradients collapse. The cell lyses.
Gram-negative bacteria add a step. HNP-1 first displaces the Mg2+ and Ca2+ cations stabilizing LPS in the outer membrane. Only after breaching that barrier does it reach the inner membrane for pore formation. Against enveloped viruses like HIV-1, HNP-1 disrupts glycoprotein-mediated fusion and damages the viral lipid envelope directly [1].
The immunomodulatory pathway runs through CCR6 receptors on immature dendritic cells and memory T cells. HNP-1 is a chemoattractant, pulling these cells toward infection sites. It then promotes dendritic cell maturation by upregulating CD80, CD86, CD83, and MHC class II (Yang et al., 1999)[3]. Macrophage activation occurs via TLR4-dependent signaling, increasing phagocytic capacity and triggering NF-kB-driven release of TNF-alpha, IL-1beta, and IL-6. HNP-1 also activates complement by binding C1q and initiating the classical pathway.
Defensin (HNP-1) Benefits
- Defensin HNP-1 benefits center on antimicrobial defense and innate immune activation.
- Kills bacteria, fungi, and enveloped viruses through direct membrane pore formation. In vitro MIC values range from 1 to 10 mcg/mL across tested pathogen panels (Ganz, 2003)[4].
- Recruits dendritic cells, monocytes, and naive T cells via CCR6 binding. This chemotactic function connects innate and adaptive immunity, a property confirmed in Yang et al.'s 1999 work [3].
- Activates macrophage phagocytosis through TLR4/NF-kB signaling, increasing pathogen clearance capacity in animal models.
- Boosts complement activation by binding C1q and triggering the classical pathway, adding another layer of immune defense beyond direct killing.
- Selective cytotoxicity against certain cancer cell lines has been observed in vitro. Colorectal and bladder cancer studies have identified raised HNP-1 serum levels as potential biomarkers, though whether this is protective or simply reflects neutrophil activation remains unresolved.
- HNP-1 makes up 5 to 7 percent of total neutrophil protein, making it one of the most abundant antimicrobial peptides in the human body. That biological prevalence suggests it plays a load-bearing role in first-line pathogen defense.
Defensin (HNP-1): Science vs Community Consensus
No human clinical trials exist.
Read the evidence (key study, limitations)
~1,000 PubMed publications cover defensin biology, but all human-relevant data is observational (endogenous levels) or extrapolated from in vitro MIC values and rodent models. Broad-spectrum antimicrobial and immunomodulatory activity well-established in basic science; exogenous therapeutic use unvalidated in humans.
PMC11858525 (2025): structure-to-application review; PMID 12949495 (Ganz 2003): foundational antimicrobial peptide review; PMC11981803 (2025): HNP-1 activates SaeRS virulence system in S. aureus
Zero Phase I/II/III clinical data. Manufacturing barrier: three intramolecular disulfide bonds require expensive synthetic chemistry. No formal PK study in any species for SC route. Critical HIV paradox: HNP-1 both inhibits cell-free HIV (PMID 15719067) and increases HIV mucosal traversal (PMID 26379091). High-dose sepsis worsening (PMC9355784) complicates use in any infection context.
No organized self-experimentation community found.
Read the reports (common issues 1)
Fewer than 20 Reddit threads, all academic/discussion rather than protocol-sharing. No anecdotal dosing reports, stacking logs, or outcome data. This compound exists solely in research contexts.
- No community experience to report: research-only compound with no accessible consumer market
Research exists (1,000+ papers on defensin biology) but no community self-experimentation exists. All dosing tiers are researcher-extrapolated estimates from in vitro MIC data, not real-world validated.
Defensin (HNP-1) Dosage Guide
HNP-1 is not part of the standard research-peptide market. Research-grade material, sold only as a lab reagent, runs roughly $250 to $400 per 0.1 mg. That price is telling you something about manufacturing difficulty.
Reconstitution math for a 1 mg vial: add 2 mL bacteriostatic water to get 500 mcg/mL. A 50 mcg beginner dose is 0.10 mL (10 units on a U-100 insulin syringe). A 100 mcg moderate dose is 0.20 mL (20 units). A 200 mcg aggressive dose is 0.40 mL (40 units).
Swirl gently when reconstituting. Defensins aggregate at air-water interfaces; shaking or vortexing will ruin your vial. If you see cloudiness after reconstituting, the product may be aggregated and should be discarded.
A useful Certificate of Analysis includes disulfide bond confirmation by mass spectrometry or NMR. Standard HPLC purity testing does not confirm the three disulfide bonds formed correctly. Misfolded HNP-1 is inactive or potentially cytotoxic.
Get baseline bloodwork before starting: CBC with differential, CRP, ESR, and liver function panel.
Cycling Protocol
No established human cycling protocols exist. The 8-on/4-off recommendation is conservative and based on general immune peptide cycling principles. Monitor inflammatory markers (CRP, ESR) during use. Discontinue if signs of excessive inflammation develop.
Exogenous HNP-1 is an endogenous human peptide, but supraphysiological exogenous administration can trigger anti-defensin antibodies that may alter endogenous innate immune function. Chronic pro-inflammatory cytokine elevation (TNF-α, IL-1β, IL-6) also warrants periodic washout to prevent cumulative endothelial and atherosclerotic risk. No receptor desensitization mechanism is established.
- Declining injection site inflammatory response over repeated doses (possible tolerance development or antibody neutralization)
- Rising CRP/ESR on consecutive bloodwork suggesting cumulative inflammatory load
- Signs of HNP-1-linked endothelial effects: new telangiectasias, unexplained blood pressure changes
- Any autoimmune-like symptom onset: joint pain, unexplained rash, or disproportionate fatigue relative to injection timing
Or use the universal Peptide Calculator for any peptide.
Defensin (HNP-1) Protocols by Goal
Expected: Theoretical: enhanced innate immune activation (macrophage, DC, NK cell priming). No validated human outcome data exists. Observable markers: CBC with differential, inflammatory cytokines (TNF-α, IL-1β) if lab monitoring enabled.
Monitor: CBC with differential at baseline and week 4/8. CRP and ESR at baseline and week 4. Liver function panel recommended given PMC9355784 liver junction disruption finding at high doses.
How to Inject Defensin (HNP-1)
- 1Pull 2 mL of bacteriostatic water into a syringe
Inject slowly against the inner wall of the vial containing 1 mg lyophilized HNP-1. This yields a concentration of 500 mcg/mL.
- 2Swirl the vial gently until the powder dissolves completely
Do not shake, vortex, or invert vigorously. Defensins aggregate at air-water interfaces. A clear solution confirms proper reconstitution.
- 3Draw your dose using a U-100 insulin syringe
Beginner: 10 units (50 mcg). Moderate: 20 units (100 mcg). Aggressive: 40 units (200 mcg).
- 4Choose an injection site on the abdomen
Rotate sites with each injection to minimize local tissue irritation from the cationic charge.
- 5Step 5
Use a 29 to 31 gauge needle (most insulin syringes come with 30 gauge). Pinch a fold of skin, insert at a 45-degree angle, inject slowly. Hold for 5 seconds before withdrawing.
- 6Inject at a consistent time each day
Morning is commonly chosen for immune peptides, though no HNP-1-specific timing data exists.
- 7Step 7
Start at the beginner dose (50 mcg, 3 times per week) for the first 1 to 2 weeks. Only increase to daily 100 mcg if no excessive injection site inflammation develops.
- 8Step 8
Store reconstituted vials upright in the refrigerator at 2 to 8 degrees C. Use within 14 days. Do not freeze reconstituted solution.
- 9Cycle 8 weeks on, 4 weeks off
Get bloodwork at baseline, week 4, and week 8 (CBC with differential, CRP, ESR, liver panel).
Defensin (HNP-1) Stacking Protocols
Works With
Complementary immune modulation via different pathway (thymic T-cell maturation vs. neutrophil/innate priming). TA-1 has actual human trial data (hepatitis B/C, cancer immune support) making the stack more grounded than HNP-1 alone.
TA-1 0.5–1.6 mg SC 2×/week alongside conservative HNP-1 protocol; monitor additive inflammatory signals
Cathelicidin AMP with overlapping antimicrobial/immunomodulatory activity; distinct receptor targets (FPRL1/FPR2 vs. CCR6). Both are endogenous host defense peptides with a theoretical combined innate immune effect.
LL-37 100–200 mcg SC daily alongside conservative HNP-1 dosing; monitor additive inflammatory signals closely
Avoid
HNP-1 activates macrophages and promotes pro-inflammatory cytokines via NF-κB, directly opposing immunosuppressive therapy. In transplant recipients, risks graft rejection.
Do not combineHNP-1 neutralizes heparin's anticoagulant activity through direct binding. May unpredictably alter anticoagulation parameters.
Do not combineCombined immune activation effects unstudied. Theoretical risk of excessive immune activation or cytokine storm from dual checkpoint + innate immune stimulation.
Estimated Cost
Defensin (HNP-1) Side Effects
The most serious concern with exogenous HNP-1 is host cell cytotoxicity. At high concentrations, alpha-defensins damage mammalian epithelial and endothelial cell membranes through the same pore-forming mechanism they use on microbes. This is concentration-dependent, not idiosyncratic. Higher doses mean more membrane disruption, and there is no established safe ceiling in humans.
A mouse study (PMC9355784) found that high-dose exogenous HNP-1 at 10 mg/kg i.p. disrupted liver interendothelial junctions through the NLRP3 inflammasome/caspase-1 pathway. Animals in that study had worsened sepsis outcomes. The dose was 175 to 3,500 times higher than research tiers listed here, but the mechanism is concerning enough that liver function monitoring (ALT, AST) is recommended even at conservative doses.
Pro-inflammatory cytokine elevation is expected, not a side effect to be dismissed. HNP-1 activates NF-kB, driving TNF-alpha, IL-1beta, and IL-6 release. For someone with underlying autoimmune disease, this could trigger a flare. For anyone on immunosuppressive therapy, it directly opposes the mechanism of drugs like tacrolimus and cyclosporine.
Injection site reactions are predicted based on the peptide's cationic charge. Redness, swelling, and pain at the injection site reflect local tissue interaction with a positively charged peptide. If injection site inflammation becomes excessive, that signals local cytotoxicity, not an allergic reaction. Reducing dose or frequency is the appropriate response.
The HIV paradox is not theoretical. HNP-1 kills cell-free HIV in laboratory assays [1]. But a 2015 study in epithelial cell models [2] showed that HNP-1 disrupts epithelial tight junctions, increasing HIV traversal of mucosal barriers. Anyone who is HIV-positive or at high risk of HIV exposure should consider this an absolute contraindication.
Raised endogenous defensin levels have been associated with atherosclerosis and endothelial dysfunction in observational studies. Extended exogenous use could theoretically worsen cardiovascular risk, particularly in someone with existing vascular disease.
No formal human adverse event profiles exist. HNP-1 has never entered a Phase I trial. The total number of humans who have received exogenous HNP-1 as a therapeutic agent is effectively zero.
When to stop: fever above 38 degrees C, any sign of worsening infection, autoimmune flare symptoms (joint pain, unexplained rash, disproportionate fatigue), liver enzymes rising above 2x the upper limit of normal, or any identified HIV exposure risk. Do not attempt to push through these signals.
Pregnancy and breastfeeding: no reproductive safety data of any kind. This is a hard contraindication.
Common Issues & Solutions
Excessive injection site redness/swelling (local cytotoxicity): reduce dose or frequency: this is concentration-dependent host cell membrane interaction, not allergy; cytotoxicity is the primary theoretical risk of exogenous HNP-1.
Worsening infection symptoms after starting: STOP immediately: high-dose HNP-1 (PMC9355784) disrupts liver interendothelial junctions via NLRP3/caspase-1, worsening sepsis outcomes; never use during active infection.
Cloudy/aggregated reconstituted vial: defensins aggregate at air-water interfaces; reconstitute by gentle swirling only (no shaking); discard if aggregation persists: injecting aggregated product risks local cytotoxic reaction.
HIV exposure concern identified: CONTRAINDICATED: HNP-1 paradoxically increases HIV traversal of mucosal epithelial barriers [2] by disrupting tight junctions; this is an absolute contraindication for HIV+ individuals and high-risk settings.
No measurable immune benefit after 4 weeks: expected finding: no validated human biomarker response exists; all outcome monitoring is exploratory; discontinue if monitoring shows concerning inflammatory or hepatic trends.
Ask AI about this page
Ask AI for a second opinion on Defensin (HNP-1) dosing and side effects
Contraindications
- Active autoimmune disease: HNP-1 stimulates pro-inflammatory cytokines and immune cell recruitment
- Acute respiratory distress syndrome (ARDS) or severe pulmonary inflammation
- Active atherosclerosis or cardiovascular disease: HNP-1 linked to endothelial dysfunction
- Organ transplant recipients on immunosuppressants: immune activation risks graft rejection
- Pregnancy or breastfeeding: no reproductive safety data
- Sepsis or systemic inflammatory response syndrome (SIRS)
Drug Interactions
- Immunosuppressants (cyclosporine, tacrolimus, mycophenolate): HNP-1 immune-activating effects may counteract immunosuppressive therapy
- Corticosteroids: may reduce endogenous defensin release; exogenous HNP-1 effects may be blunted
- Anticoagulants (heparin, warfarin): HNP-1 can neutralize heparin's anticoagulant activity
- Other antimicrobial peptides (LL-37, Thymosin Alpha 1): additive or greater immune stimulation
- Checkpoint inhibitors (nivolumab, pembrolizumab): combined immune activation effects unstudied
- NSAIDs: may partially counteract HNP-1-induced pro-inflammatory signaling
- HNP-1 activates macrophages and promotes pro-inflammatory cytokines via NF-κB, directly opposing immunosuppressive therapy. In transplant recipients, risks graft rejection.
- HNP-1 neutralizes heparin's anticoagulant activity through direct binding. May unpredictably alter anticoagulation parameters.
Product Quality
HNP-1 requires three precisely-formed intramolecular disulfide bonds (Cys2-Cys30, Cys4-Cys19, Cys9-Cys29) that are critical for biological activity. Misfolded or partially oxidized product is biologically inactive or potentially cytotoxic, yet indistinguishable from active material by standard HPLC purity testing alone. Research-grade material is extremely expensive (~$250–400 per 0.1 mg as a lab reagent), effectively limiting the market to serious research labs. No compounded versions exist. Consumer/gray-market availability is essentially zero: this is not a standard peptide market item. The 2025 PMC11858525 review specifically cites production fidelity as the primary barrier to clinical translation.
- HNP-1 is sold only as a lab reagent for research; disulfide bond verification is the key quality marker.
- A useful CoA includes disulfide bond confirmation by mass spectrometry or NMR: a standard HPLC purity certificate does not confirm correct folding.
- Reconstitute by gentle swirling only (no vortexing or shaking): defensins aggregate at air-water interfaces; aggregated product may be inactive or cytotoxic.
- Use reconstituted solution within 14 days; do not freeze reconstituted vials.
- Given cost (~$125–200 per 50 mcg dose from 0.1 mg research vials), plan full protocol before reconstituting to avoid waste.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| CBC with differential | Baseline, week 4, week 8 | WBC 4.5–11.0 K/µL; neutrophils 1.8–7.7 K/µL; no significant shift from baseline expected at research doses |
| C-Reactive Protein (CRP) | Baseline, week 2, week 4, week 8 | <3 mg/L baseline target; values >10 mg/L warrant dose reduction or discontinuation |
| Erythrocyte Sedimentation Rate (ESR) | Baseline, week 4, week 8 | <20 mm/hr (age-adjusted); rising trend warrants reassessment |
| Liver function panel (ALT, AST, ALP) | Baseline, week 4 | ALT <56 U/L, AST <40 U/L; any elevation >2× ULN warrants discontinuation |
Track neutrophil/monocyte/lymphocyte changes reflecting HNP-1 immunomodulation; detect unexpected cytopenias
HNP-1 stimulates pro-inflammatory cytokines (TNF-α, IL-1β via NF-κB); CRP monitors for excessive systemic inflammation
Secondary inflammatory marker; elevated in autoimmune and vasculitic conditions that HNP-1 could exacerbate
PMC9355784 finding: high-dose HNP-1 disrupts liver interendothelial junctions via NLRP3 inflammasome/caspase-1 pathway; hepatic monitoring warranted even at lower research doses
Defensin (HNP-1) Before and After
Treatment initiation at low dose. HNP-1 begins circulating and interacting with immune cells. Assess injection site tolerance and monitor for excessive local inflammation. Baseline bloodwork (CBC with differential, CRP, ESR) recommended.
Early immunomodulatory effects may begin. Neutrophil and monocyte activity may show subtle enhancement. Dendritic cell recruitment to peripheral tissues is theoretically increased.
Cumulative immune priming effects expected. In animal models, sustained defensin exposure produces measurable increases in macrophage phagocytic activity and dendritic cell maturation markers.
Peak treatment window. Adaptive immune bridging effects (T-cell recruitment, enhanced antigen presentation) should be most apparent. Full bloodwork recommended.
What to Expect
Week 1-2, Tolerance assessment: HNP-1 begins circulating after subcutaneous injection, with an estimated half-life of 3 to 4 hours. The cationic peptide interacts with local tissue at the injection site. Dendritic cell and monocyte chemoattraction through CCR6 binding theoretically starts during this window. Multiple injections per week are needed because the short half-life limits sustained immunomodulatory signaling. Expect injection site redness and mild swelling from the cationic charge interacting with local tissue. Mild flushing is possible from initial cytokine release. No human self-experimentation data exists for this compound; all expectations are extrapolated from animal models and peptide pharmacokinetic class data. Get baseline CBC with differential, CRP, and ESR before the first injection.
Weeks 2-4, Early immunomodulatory effects (theoretical): Macrophage phagocytic activity may start to increase. Dendritic cell recruitment via CCR6 binding should be ongoing. NK cell activation is theoretically engaged at this point. All of these projections come from in vitro and rodent data only; no human validation exists. Zero community experience is available for comparison. Watch for pro-inflammatory cytokine effects: TNF-alpha and IL-1beta elevation could produce joint pain, rash, or fatigue in susceptible individuals.
Weeks 4-8, Cumulative immune priming (animal model projection): Rodent studies show sustained defensin exposure produces measurable increases in macrophage phagocytic activity and dendritic cell maturation markers. The adaptive immunity effects (T-cell recruitment, improved antigen presentation) should be most apparent now. CRP and ESR monitoring is important during this phase; cumulative inflammatory load is a real concern. Observational data links raised HNP-1 to endothelial dysfunction, so extended use carries theoretical cardiovascular risk. Full bloodwork at week 4 and week 8, including liver function panel given the PMC9355784 finding on hepatic junction disruption at high doses.
Detailed Timeline: Science vs Community
HNP-1 circulates with estimated half-life of 3-4 hours. Electrostatic interaction with local tissue; initial DC/monocyte chemoattraction theoretically begins. Multiple injections per week required for sustained immunomodulatory signaling.
No human self-experimentation data: extrapolated from animal models and peptide PK class data only.
Macrophage phagocytic activity enhancement; dendritic cell recruitment via CCR6 binding; NK cell activation. All projections from in vitro and rodent data only: no human validation.
No reports: zero community experience available.
In rodent models, sustained defensin exposure produces measurable macrophage phagocytic upregulation and DC maturation marker increases. Adaptive immunity bridging (T-cell recruitment, enhanced antigen presentation) theoretically most apparent at this stage.
No reports available.
Pharmacokinetics
Source: No formal PK studies of exogenous HNP-1 in humans. Estimated 3-4 hours based on cationic peptide clearance kinetics for peptides in the 3-4 kDa range.
Pharmacokinetics: Active Dose Over Time
t½ = ~3-4 hours (estimated, based on peptide clearance kinetics)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Defensin (HNP-1) Legal?
HNP-1 holds research-only status with no FDA approval for any therapeutic indication. It has never entered a Phase I, II, or III clinical trial. The compound is sold only as a lab reagent for in vitro and animal research purposes.
HNP-1 is not on the 503A bulks list (21 CFR 216.23) and appears in no FDA 503A or 503B nomination category (lists updated May 14, 2026 and March 21, 2025). The three disulfide bonds required for correct folding make production difficult and expensive, limiting availability to specialized chemical synthesis houses.
HNP-1 is not named on WADA's 2026 Prohibited List. Its S0 class covers any substance with no current approval by a government health authority, and HNP-1 has none, so S0 reads onto it. S0 substances are prohibited in and out of competition. Athletes subject to testing should verify current WADA guidance before use.
This content is for educational and research reference purposes only. It does not constitute medical advice. No information on this page should be interpreted as recommending the use of HNP-1 for any clinical purpose. Consult a qualified healthcare provider before making any decisions about peptide research or use.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider Defensin (HNP-1)
- Researchers studying innate immune defense mechanisms and antimicrobial peptides
- Scientists investigating host defense peptide-based approaches to antibiotic resistance
- Researchers exploring defensin-based antitumor peptide strategies
- Immunologists studying dendritic cell maturation and adaptive immunity bridging
- Individuals with recurrent infections seeking immune support under medical supervision
Related Peptides
What Changed for Defensin (HNP-1)
- Evidence
Corrected Oct 12, 2026: the HNP-1 HIV warning now cites one in vitro study in epithelial cells, after dropping an unrelated paper, per PubMed (PMID 26379091).
Before: Demirkhanyan et al. (PMID 22647697, 2012) and a 2015 study (PMID 26379091) showed HNP-1 disrupts epithelial tight junctions, increasing HIV traversal After: A 2015 study in epithelial cell models (PMID 26379091) showed HNP-1 disrupts epithelial tight junctions, increasing HIV traversal
What this does not mean: The warning is unchanged: anyone HIV-positive or at high risk of HIV exposure should treat HNP-1 as contraindicated.
Source: Viral Immunol 2015, Human Alpha-Defensin HNP1 Increases HIV Traversal of the Epithelial Barrier (Valere et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 8, 202613 Citations
References
- [1]Human defensins inhibit HIV replication in vitro (Chang et al., 2005) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Human Alpha-Defensin HNP1 Increases HIV Traversal of the Epithelial Barrier: A Potential Role in STI-Mediated Enhancement of HIV Transmission (Viral Immunol 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 (Yang et al., 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Defensins: antimicrobial peptides of innate immunity (Ganz, 2003) (opens in a new tab)PubMed (opens in a new tab)Review
Additional References
- Crystal structure of human defensin HNP-3, an amphiphilic dimer (Hill et al., 1991) (opens in a new tab)PubMed 2006422PubMed
- Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? (Brogden, 2005) (opens in a new tab)PubMed 15703760Review
- PMC9355784 (PMC9355784) (opens in a new tab)PubMed
- PMC11858525 (PMC11858525) (opens in a new tab)PubMed
- Human neutrophil defensin-1 binding increases histidine kinase activity of SaeS in Staphylococcus aureus (Biochem Biophys Rep 2025) (opens in a new tab)PubMed 40207086PubMed
- FDA: Bulk drug substances nominated for use in compounding under section 503A, categories (updated May 14, 2026) (opens in a new tab)Review
- FDA: Bulk drug substances nominated for use in compounding under section 503B, categories (updated March 21, 2025) (opens in a new tab)Review
- 21 CFR 216.23: Bulk drug substances that can be used to compound drug products under section 503A (eCFR) (opens in a new tab)Review
- World Anti-Doping Agency, 2026 Prohibited List: S0 non-approved substances, prohibited at all times (opens in a new tab)Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Defensin (HNP-1)?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 20. Community mentions on Reddit: <20 threads.
1,000 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Minimal search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.